Physicians' Academy for Cardiovascular Education

The expanding role of ARB’s in CV risk management

Slides (presentation) - Jan. 29, 2011

The expanding role of ARB’s in CV risk management:
Does it matter how we block the system?


Peter Meredith, PhD
University of Glasgow
Glasgow, United Kingdom
CDMC - Shanghai - January 2011





Click on slides to view presentation


The Renin Angiotensin System: ACE Inhibition
The Renin Angiotensin System: AT1 Blockade
RAAS Blockade Across the CV Continuum
2007 ESH/ESC Guidelines
Effect of Different Antihypertensives on Incident Diabetes
Quality of Life and Antihypertensive Treatment
Persistence with Antihypertensive Therapy
ACEIs vs ARBs: Risk of Stroke
ACEIs vs ARBs: Risk of Myocardial Infarction
Antihypertensive Therapy & Type 2 Diabetes
AT1 Receptor Blockers in Type 2 Diabetes
Comparison of Enalapril & Candesartan Cilexetil:
Chemical Structures of Angiotensin II Receptor Blockers
Insurmountable and Surmountable Antagonism
Number of AT1-Receptor Binding Sites
Potential Benefits of Additional BP Reductions
The Cardiovascular Continuum
Conclusions

Download slides

Share this page with your colleagues and friends: